Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + Chemotherapy in Newly Diagnosed CBF AML
NCT01238211Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Jul 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in Core-binding factor acute myeloid leukemia (CBF-AML), sponsored by National Cancer Institute. Primary endpoints: Safety and Tolerability of Dasatinib, 30-Day Survival Rate and 1 more. Started Dec 2010; status: completed.
02
Drugs
dasatinib
03
Conditions
Core-binding factor acute myeloid leukemia (CBF-AML)
Beyond the preview
Go deeper on NCT01238211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01238211.